Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36705644/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Ide-cel was associated with significant survival improvements in terms of both LYs and QALYs in patients with progressive triple-class-exposed RRMM. The ICER for ide-cel was similar to that of other approved and reimbursed RRMM therapies.
Is t(11;14)(q13;q32) good or bad for newly diagnosed... : Chinese Medical Journal
Source : https://journals.lww.com/cmj/Fulltext/9900/Is_t_11_14__q13_q32__good_or_bad_for_newly.309.aspx
1 Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China 2 Peking University People's Hospital, Peking University Institute of Hematology, Cytogenetics Laboratory, Beijing Key Laboratory of Hematopoietic...
Conclusions: This single-center, retrospective study showed that patients harboring t(11;14) had comparable survival to patients without any high-risk cytogenetics. Gain/amp of 1q21 was an adverse prognostic risk factor for patients with t(11;14) myeloma, a finding that provides a better understanding of this particular type of myeloma.
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma - International Journal of Hematology
Source : https://link.springer.com/article/10.1007/s12185-023-03538-6
Background In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR)...
Conclusions: Ide-cel yielded deep, durable responses with a tolerable and predictable safety profile in Japanese patients with RRMM. These results are similar to those of the non-Japanese population in KarMMa.
Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36651055/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: These findings hinge on the assumption of longer-term survival but suggest that the use of CAR-T therapy is approaching standard ICER thresholds.
"
Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36648884/
In recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non-CAR-T agents. Since direct comparisons between these innovative treatments...
Conclusions: While the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies.